Table 2 The correlations between the ALI (and its components) and the clinicopathological factors
ALI | BMI (kg/m2) | Albumin (g/dl) | NLR | |||||
|---|---|---|---|---|---|---|---|---|
Median (range) | p-value | Median (range) | p-value | Median (range) | p-value | Median (range) | p-value | |
Age | ||||||||
< 65 | 34.17 (4.68–174.81) | 21.73 (15.48–29.91) | 4.0 (2.7–4.9) | 2.66 (0.71–12.57) | ||||
≥ 65 | 38.52 (4.61–175.07) | 0.367 | 21.50 (15.30–33.76) | 0.683 | 3.8 (2.5–4.8) | 0.023 | 2.18 (0.58–13.56) | 0.112 |
Gender | ||||||||
Male | 38.42 (4.61–174.81) | 21.80 (15.32–29.91) | 3.9 (2.5–4.7) | 2.44 (0.71–13.56) | ||||
Female | 36.81 (7.41–175.07) | 0.341 | 20.88 (15.30–33.76) | 0.246 | 3.9 (2.9–4.9) | 0.714 | 2.41 (0.58–8.85) | 0.459 |
Location of primary tumor | ||||||||
Right side | 41.44 (4.61–175.07) | 22.05 (15.32–33.76) | 3.9 (2.7–4.8) | 1.95 (0.58–13.56) | ||||
Left side | 33.70 (7.41–109.73) | 0.137 | 21.39 (15.30–29.91) | 0.628 | 3.95 (2.5–4.9) | 0.617 | 2.53 (0.94–8.85) | 0.069 |
Histological type | ||||||||
Well, Moderately | 36.81 (4.61–175.07) | 21.50 (15.30–33.76) | 3.9 (2.5–4.9) | 2.48 (0.58–13.56) | ||||
Poorly, Mucinous | 39.39 (12.96–101.80) | 0.442 | 21.79 (16.98–27.34) | 0.962 | 3.9 (3.2–4.6) | 0.786 | 2.03 (1.05–4.95) | 0.375 |
RAS status | ||||||||
Wild type | 40.35 (4.61–109.73) | 21.20 (15.30–33.76) | 4.1 (2.5–4.8) | 2.08 (0.94–13.56) | ||||
Mutant type | 37.29 (4.68–175.07) | 0.203 | 21.80 (16.00–29.91) | 0.652 | 4.0 (2.7–4.9) | 0.829 | 2.66 (0.58–12.57) | 0.075 |
Detection of unresectable tumor | ||||||||
Synchronous | 28.98 (4.61–175.07) | 21.49 (16.00–33.76) | 3.85 (2.5–4.8) | 2.69 (0.58–13.56) | ||||
Metachronous | 40.43 (9.31–109.73) | 0.016 | 22.02 (15.30–29.29) | 0.680 | 4.0 (3.1–4.9) | 0.020 | 2.08 (0.97–6.33) | 0.028 |
The number of organs affected by metastasis | ||||||||
One organ | 38.21 (7.41–175.07) | 21.30 (15.30–29.91) | 3.9 (2.5–4.9) | 2.41 (0.58–7.77) | ||||
Multiple organs | 36.13 (4.61–174.81) | 0.968 | 21.80 (16.89–33.76) | 0.535 | 3.9 (2.7–4.8) | 0.718 | 2.48 (0.71–13.56) | 0.930 |
Peritoneal dissemination | ||||||||
Negative | 35.42 (7.41–175.07) | 21.60 (15.30–33.76) | 3.9 (2.5–4.9) | 2.52 (0.58–8.85) | ||||
Positive | 39.39 (4.61–98.33) | 0.365 | 21.86 (16.98–25.65) | 0.339 | 4.0 (2.7–4.7) | 0.190 | 2.04 (0.94–13.56) | 0.282 |
Molecular targeted therapy | ||||||||
Without | 35.15 (11.17–174.81) | 22.44 (16.12–33.76) | 3.85 (2.5–4.8) | 2.42 (0.71–6.07) | ||||
With | 38.42 (4.61–175.07) | 0.977 | 21.00 (15.30–29.91) | 0.105 | 4.0 (2.7–4.9) | 0.281 | 2.41 (0.58–13.56) | 0.986 |